GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vifor Pharma AG (LTS:0RPD) » Definitions » Buyback Yield %

Vifor Pharma AG (LTS:0RPD) Buyback Yield % : 0.02 (As of May. 10, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Vifor Pharma AG Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Vifor Pharma AG's current buyback yield was 0.02%.


Vifor Pharma AG Buyback Yield % Historical Data

The historical data trend for Vifor Pharma AG's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vifor Pharma AG Buyback Yield % Chart

Vifor Pharma AG Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 0.23 0.08 0.28 0.02

Vifor Pharma AG Semi-Annual Data
Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.54 0.09 0.15 -0.06

Competitive Comparison of Vifor Pharma AG's Buyback Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Vifor Pharma AG's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vifor Pharma AG's Buyback Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vifor Pharma AG's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Vifor Pharma AG's Buyback Yield % falls into.



Vifor Pharma AG Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Vifor Pharma AG's Buyback Yield for the fiscal year that ended in Dec. 2021 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-5.8 + 3.2) / 10577.2819
=0.02%

Vifor Pharma AG's annualized Buyback Yield for the quarter that ended in Dec. 2021 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (3.2 + 0) * 2 / 10577.2819
=-0.06%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized semi-annual data, the Repurchase of Stock and Issuance of Stock data used here is two times the semi-annual (Dec. 2021) data.


Vifor Pharma AG Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Vifor Pharma AG's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vifor Pharma AG (LTS:0RPD) Business Description

Traded in Other Exchanges
N/A
Address
Rechenstrasse 37, Saint Gallen, CHE, 9014
Vifor Pharma AG is a specialty drug manufacturing and licensing company. It researches, develops, and produces its pharmaceutical products and markets and distributes them worldwide. Most of its sales are generated in the USA, with Europe also a strong contributor. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Vifor Pharma AG (LTS:0RPD) Headlines

No Headlines